Kornimate/medical-research-clean huggingface dataset:
cardboard cot in neonatal thermoregulation: a randomized cross over trial

Conditions: Infant, Premature; Hypothermia, Newborn

Summary: this study will determine whether the efficacy of mylar-lined cardboard cots is equivalent to traditional incubators in their ability to prevent hypothermia (axillary temperature \< 36° c) in preterm neonates \<36 6/7 weeks gestational age in a randomized cross-over designed trial. infants will be randomized to receive care in the cardboard cot or incubator and then cross over to the other device for 24 hour periods, rotating for a total of 96 hours total trial time.

the aim of the trial is to determine whether a corrugated cardboard cot will assist in maintaining infant axillary temperatures comparing it to the temperatures of the same infant being nursed in low heat incubators. the study will be done in the context of standard medical care, including the who thermoregulation protocol (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling). the cardboard cot is approximately 24 inches long to accommodate the length of the infant and about 12 inches wide to accommodate term infants, even beyond the first months after birth. the cots are fully lined with a reflective metallized film sheet of mylar. the cot will be covered with a cardboard piece also lined in reflective film up to about the infant's shoulders so that the infant's face is visible. attached to the lid is a 5 inch cardboard flap lined with reflective film which folds down into the body of the cot to reduce heat loss. infants ≤ 36 6/7 weeks gestation will be randomized to receive care in a cardboard cot or an incubator. infants will begin care in one device and after 24 hours will cross over to the other device for another 24 hours. the process will be repeated once more for a total of 96 hours of study duration. the infants will be normothermic and stable when they are enrolled in the trial. axillary temperatures will be measured at 1 hr, 6 hours and 24 hours after being placed in the cost or incubator. infants with observed hypothermia (\<36° c) will have measures taken to increase temperature (i.e. adding blankets, hat).

Eligibility criteria:
inclusion criteria: * estimated gestational age \< 36 6/7 weeks * hospitalized in the nicu at university teaching hospital in zambia * requiring incubator/radiant warmer for at least 1 week exclusion criteria: * abdominal wall defect or myelomeningocele * major congenital anomalies * blistering skin disorder * suspected sepsis * requiring ongoing respiratory support

Keywords: neonate premature hypothermia cardboard cot
acute care for elders (ace) program at ohsu hospital

Conditions: Delirium; Age-Related Cognitive Decline; Frail Elderly; Hospital Acquired Pressure Ulcer; Drug-Related Side Effects and Adverse Reactions

Summary: the purpose of this investigation is to assess the effectiveness of a multi-disciplinary acute care for elders (ace) program dedicated to the care of patients age 70 and older admitted to oregon health \& science university's hospital medicine service. the ace program will aim to improve the quality of care of older patients in the investigators hospital by implementing focused interventions and recommendations specific to geriatric needs and syndromes, including: reduced fall rate, decreased incidence and duration of delirium, early recognition and treatment of impaired mobility and function, careful minimization of medication use, prevention of unnecessary catheter and restraint use, decreased hospital readmission rates, improved transitional care following hospital discharge, and high levels of patient and referring physician satisfaction. additionally, the ace program aims to improve resident and student competence in treating geriatric syndromes, and to improve staff and learner satisfaction with caring for older adults. ace programs have been well studied at other institutions, so the investigators will be implementing a program that is already standard of care, and studying the elements that are unique to ohsu. this will be a quality improvement project. study participants will be a convenience sample of ohsu faculty, staff, residents and students who are employed by or on rotation with general medicine team 1 of the medicine teaching service. faculty, staff, and learners (ace team members) will receive the ace training. study personnel will conduct prospective and retrospective chart review of patients admitted to the ace service to determine outcomes as noted above.


Eligibility criteria:
inclusion criteria (ace faculty, health care providers and students): * employed by ohsu or enrolled in one of ohsu's schools (medicine, nursing, pharmacy) * share in the care of older adults on the general medicine team 1 service. inclusion criteria (patients): * admitted to the internal medicine service during the time frame of the study * age 70 or older at time of hospital admission exclusion criteria (ace faculty, health care providers and students): * non-english-speaking exclusion criteria (patients): * none

Keywords: geriatrics acute care for elders geriatric syndromes delirium falls polypharmacy
bibf1120 in patients with advanced fgfr3 mutated,overexpressed,or wild type urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: bibf1120 in patients with advanced fgfr3 mutated, fgfr3 overexpressed, or fgfr3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.


Eligibility criteria:
inclusion criteria: * kps 60% * histological confirmation of urothelial carcinoma , with metastatic disease * measurable disease * previously treated with platinum-based chemotherapy administered exclusion criteria: * radiographic evidence of cavitary or necrotic tumours * active brain metastasis.leptomeningeal metastasis * chemotherapy, radiotherapy, targeted therapy with monoclonal antibodies or small tyrosine kinase inhibitors * grade 1 treatment-related toxicity from previous chemotherapy, radiotherapy, or targeted therapy * prior treatment with bibf 1120 or other vegfr inhibitors * significant cardiovascular diseases: * pericardial effusion * significant bleeding or thrombosis * gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug * major injuries within the past 10 days with incomplete wound healing and/or planned surgery during the on-treatment study period

Keywords: urothelial carcinoma bibf1120
the comparative trial of uft + tam with cmf + tam in adjuvant therapy for breast cancer (cubc)

Conditions: Breast Cancer

Summary: this controlled study is designed to evaluate the relapse-free survival of uft + tam compared with cmf + tam. patients are randomly assigned to receive either cmf + tam or uft + tam within 6 weeks after surgery. to assess treatment efficacy, data on recurrence and survival will be collected for 5 years after surgery. to evaluate the safety, data on adverse events will be collected during treatment. patients'quality of life will be assessed by means of a questionnaire.


Eligibility criteria:
inclusion criteria: * age 20 to 65 * hematopoietic wbc ≥ 4,000/mm\^3 platelet ≥ 100,000/mm\^3 hemoglobin ≥ 11.0 g/dl * hepatic ast and alt ≤ 40 u/l total bilirubin ≤ 1.5 mg/dl * renal bun ≤ 25 mg/dl creatinine ≤ 1.5 mg/dl

Keywords: breast cancer
peri-operative foot ct perfusion in cli patients

Conditions: Critical Limb Ischemia

Summary: to investigate the clinical value of quantitative analysis of peri-operative foot supply through ct perfusion in patients with critical limb ischemia


Eligibility criteria:
inclusion criteria: * 18 to 80 years old; * cli patients with fontaine grade iii-iv or rutherford grade 4-6 and underwent a successful revascularization; * patients completed both pre- and post-operative ctp workups; * patients signed the informed consent form and be able to complete the clinical follow-up for 12 months. exclusion criteria: * patients has participated in other clinical studies; * patients with heart failure (nyha iii/iv)/right to left shunt heart disease/severe aortic and mitral insufficiency/acute coronary syndrome/malignant arrhythmia/severe pulmonary hypertension (pulmonary artery pressure at least 90 mmhg)/moderate to severe renal insufficiency (creatinine clearance rate\<60 ml/min) * any allergic constitution; * pregnancy and childbirth; * life expectancy\<12 months.
haemodynamic effects of oxytocin and carbetocin

Conditions: Pregnancy Related; Cesarean Section; Complications; Adverse Reaction to Oxytocic Agents

Summary: the purpose of this study is to evaluate the immediate effects of carbetocin and oxytocin on maternal hemodynamic parameters (heart rate and blood pressure) in a non-invasive setup (taskeforce®-monitor) during primary caesarean section.

as there is a trend toward childbearing in later life, pre-existing maternal cardiovascular problems may become more frequent during pregnancy and at delivery. in addition the increasing number of women with congenital or acquired cardiac diseases may not tolerate the induced haemodynamic changes as well as healthy patients. therefore uterotonic drugs must be safe for the cardiovascular system. currently oxytocin is used as a common uterotonic agent in obstetrics. the use of this drug in uterotonic reasons can cause serious haemodynamic side effects which has been shown by several investigators. preliminary clinical observations of maternal heart rate and blood pressure suggest that that the use of carbetocin causes less hemodynamic changes than oxytocin. primary objective(s): to evaluate the effect of carbetocin on maternal hemodynamic parameters (heart rate, blood pressure, systemic vascular resistance, cardiac output, stroke volume, heart rate variability, and blood pressure variability) in a non-invasive setup (taskeforce®-monitor) during primary caesarean section. to compare the haemodynamic changes of carbetocin versus oxytocin. secondary objective(s) to evaluate the need of additional drugs and methods to control uterine tone.

Eligibility criteria:
inclusion criteria: * healthy pregnant women undergoing elective caesarean section with regional anesthesia exclusion criteria: ---women with * placenta praevia * placental abruption * multiple gestation * pregnancy related complications and disorders (i.e. preeclampsia, gestational diabetes) * pre-existing diseases (e.g. insulin-dependent diabetes, cardiovascular or renal diseases, thyroid disease * taking medication with known impact on the cardiovascular system * undergoing caesarean section with general anesthesia * secondary caesarean section

Keywords: caesarean section cardiovascular effects postpartum hemorrhage carbetocin oxytocin
auricular acupressure and limb massage for neuropathic pain in spinal cord injury

Conditions: Spinal Cord Injury

Summary: this randomized controlled trial included 90 patients with spinal cord injury, divided into an experimental group and a control group (45 each). the experimental group received auricular acupressure alongside rehabilitation therapy, while the control group received body acupoint massage alongside rehabilitation therapy. the intervention targeted specific auricular and body acupoints, performed three times daily, five days a week, for three weeks.

this study is a randomized controlled trial conducted in the rehabilitation ward of national taiwan university hospital, using a convenience sampling method. a total of 90 spinal cord injury patients who meet the inclusion criteria will be recruited and randomly assigned to either the experimental group (n=45) or the control group (n=45). the experimental group will receive auricular acupressure in addition to rehabilitation therapy. the selected auricular acupoints include shenmen (tf4), subcortex (at1), liver (co12), and sympathetic (ah6a). the control group will receive body acupoint massage in addition to rehabilitation therapy. the selected body acupoints include quchi (li11), hegu (li4), sanyinjiao (sp6), and zusanli (st36). both groups will receive acupoint massage three times daily, with each acupoint being massaged for three minutes. the applied pressure will be adjusted to induce sensations of soreness, numbness, fullness, or mild pain. the intervention will be conducted five days per week for a total of three weeks.

Eligibility criteria:
inclusion criteria: 1. over 18 years old. 2. spinal cord injury due to traumatic or non-traumatic reasons. 3. within one year after spinal cord injury. 4. spinal cord injuries are classified into asia grades b to d. 5. dn4 scale ≥ 4 points and paindetect scale ≥ 19 points. 6. able to communicate in mandarin and taiwanese or able to read and write chinese. exclusion criteria: 1. the auricle and surrounding skin are injured, infected or susceptible. 2. nerve block surgery has been performed previously.

Keywords: acupressure neuropathic pain quality of life activities of daily living
cardiotoxicities in patients receiving btki

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: this is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with cll patients who are initiating treatment with a bruton's tyrosine kinase (btk) inhibitor ibrutinib or acalabrutinib.

this research study includes three visits for research blood, physical exam, and cardiac testing at baseline, 3 months, and 6 months. the study will collect the following data during the 6-month study period: * blood sample collection * electrocardiogram (ecg) * echocardiogram * cardiac magnetic resonance imaging (mri) * mobile cardiac telemetry * blood pressure measurement

Eligibility criteria:
inclusion criteria * patients with confirmed diagnosis of cll who are planned to start either ibrutinib or acalabrutinib per standard of care, in monotherapy or in combination with an anti-cd20 antibody, venetoclax, and/or a pi3k inhibitor. both treatment-naïve and relapsed or refractory cll are allowed. * no known history of paroxysmal, persistent, or permanent atrial fibrillation. exception: the study allows enrollment of up to 10 patients with a known history of paroxysmal atrial fibrillation (exploratory cohort). * no known history chronic symptomatic congestive heart failure or documented ejection fraction \< 50%. * creatinine ≤ 1.5x institutional upper limit of normal (uln). an adequate kidney function is necessary to ensure safety of iv contrast given before cardiac mri. * age ≥18 years. * ecog performance status ≤2 (karnofsky ≥60%). exclusion criteria * prior exposure to ibrutinib or acalabrutinib. * patients with a clinical contraindication to mri. * patients with childbearing potential who cannot or do not wish to use an effective method of contraception, during the study period and for 12 months after the final treatment used for the purposes of the study. * patients with any medical condition, psychiatric condition, or social situation that in the opinion of the investigator would compromise compliance with study requirements.

Keywords: chronic lymphocytic leukemia small lymphocytic lymphoma
a prospective/retrospective, observational follow-up study of chronic hepatitis b with non-alcoholic fatty liver disease.

Conditions: the Effect of NAFLD on CHB

Summary: this is a prospective/retrospective, observational follow-up study of effects of fatty liver on chronic hepatitis b. patients will join this study who undergo transient elastography with liver stiffness (ls) and cap measurements or ultrasonic examination. all recruited subjects will undergo comprehensive clinical, anthropometric and laboratory assessments at the time when transient elastography or ultrasonic examination is performed. we plan to compare the relationship between chronic hepatitis b and non-alcoholic fatty liver disease. patients will be divided into several groups based on the demand.


Eligibility criteria:
inclusion criteria: age \> 18 years, chronic hepatitis b patients - exclusion criteria: patients with chronic hepatitis c or d and human immunodeficiency virus co-infection, excessive alcohol intake (≥30 g/d for men, ≥20 g/d for women), other chronic liver diseases (e.g. primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, wilson's disease), or on medications known to induce hepatic steatosis (including corticosteroids, methotrexate, and tamoxifen), and pregnancy. -
selenious yeast in cll patients w/o indication of chemotherapy

Conditions: Chronic Lymphocytic Leukemia Stage A(0); Chronic Lymphocytic Leukemia Stage A(I); Chronic Lymphocytic Leukemia Stage A(II); Chronic Lymphocytic Leukaemia Stage B(I)

Summary: the purpose of this study is to evaluate the safety and effectiveness of selenious yeast tablets in chronic lymphocytic leukemia patients without indication of chemotherapy

a large portion of cll patients has no indications of chemotherapy when diagnosed. in patients with cll, the mean serum selenium levels are lower than normal. there is a correlation between the selenium level and the clinical stage. we discovered that sodium selenite inhibited the expression of cxcl-1 and restored the defective necroptotic pathway of cll cells together with tnf-α and z-vad in vitro. the purpose of this study is to evaluate the safety and effectiveness of selenious yeast tablets in preventing cll patients without indication of chemotherapy from disease development.

Eligibility criteria:
inclusion criteria: - newly diagnosed cll/small lymphocytic lymphoma (sll) that meets criteria below: 1. newly diagnosed (\ 5,000/mm\^3; if present, prolymphocytes should be \< 55% and immunophenotyping consistent with cll defined as:the predominant population of lymphocytes share both b-cell antigens (cluster of differentiation \[cd\]19, cd20, or cd23) as well as cd5 in the absence of other pan-t-cell markers (cd3, cd2, etc.) dim surface immunoglobulin expression restricted surface kappa or lambda light chain expression before diagnosing cll or sll, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (fish) analysis for t(11;14)(immunoglobulin h \[igh\]/cyclin d 1 \[ccnd1\]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin d1 on involved tissue biopsy 2. rai stage 0 or 1 3. previously untreated 4. asymptomatic with the plan for observation(not meet iwcll indication of chemotherapy) 5. life expectancy of at least 12 months 6. willing to provide tissue for correlative research purpose exclusion criteria: 1. concentration of serum se exceed the normal range 2. active other malignancy requiring treatment that would interfere with the assessments of this study 3. hepatitis b or c 4. autoimmune disease history 5. organ transplant recipients need to receive drug therapy 6. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Keywords: chronic lymphocytic leukemia humans prospective studies selenium
construction of a risk screening tool for new psychoactive substance misuse among adolescents and young adults

Conditions: Drug Misuse; Addiction

Summary: the goal of this observational study is to construct a risk tool available for screening young adults and adolescents at high risk of drug misuse and provides a chance for early intervention to young adults and adolescents at high risk of drug misuse, which prevent the onset and development of drug addiction in the future.the main question it aims to answer is: 1. explore the occurrence and influencing factors of new psychoactive substance misuse among young adults and adolescents; 2. construct a risk prediction model for new psychoactive substance misuse among young adults and adolescents and conduct internal verification of the model; 3. based on the results of the prediction model, select the optimal model to initially form a concise scale "screening tool for the risk of new psychoactive substance misuse among young adults and adolescents"; 4. conduct external verification of the tool, and revise and improve the screening tool, form the final version of the screening tool, and verify the application performance of the screening tool.


Eligibility criteria:
inclusion criteria: * adolescents and young adults who were aged 14-35 years; * adolescents and young adults could read and communicate in chinese were invited to participate in this study exclusion criteria: * adolescents and young adults who were unable to complete the questionnaire due to physical or psychological reasons.
effects of a probiotic in hypertension

Conditions: Hypertension

Summary: high blood pressure is a major risk factor for cardiovascular events, including stroke, heart and kidney failure. typical anti-hypertensive drugs target vessels, the kidneys or the heart. here we propose a randomized, placebo-controlled study to test the blood pressure-lowering effect of a probiotic in 110 patients with grade 1 hypertension. in addition, we will investigate glucose variability, fecal bacterial metabolome, peripheral blood effector t cell frequencies (%) and health-related quality of life.


Eligibility criteria:
inclusion criteria: * men and postmenopausal women * treated or untreated hypertension (resting office blood pressure 130-159/80-99 mmhg) * bmi 18.5 - 34.9 kg/m\^2 exclusion criteria: * secondary causes of hypertension * known target organ damage * 10 years cardiovascular risk score of \>20% * diabetes * established cardiovascular or renal disease * other serious diseases * recent use of antibiotics * specialized diets, e.g. use of probiotics comments: * two inclusion criteria were changed in june 2021 to improve recruitment * age was changed from 50-75 to 50-80 years * resting blood pressure was changed from 140-159/90-99 to 130-159/80-99 mmhg
improving adherence to recommended surveillance in breast cancer survivors

Conditions: Breast Cancer

Summary: evidence-based guidelines recommend cancer surveillance procedures for breast cancer survivors including physical examination, mammography, breast self-exam, and gynecologic follow-up. the early detection of recurrent and new cancers can best be achieved through the combined, on schedule use of these surveillance procedures. yet, data suggest that up to 55% of breast cancer survivors do not undergo these procedures as recommended. this study tests a telephone-based psychosocial intervention aimed at improving adherence to recommended surveillance in breast cancer survivors. the psychosocial intervention for improving adherence is compared to treatment as usual.


Eligibility criteria:
inclusion criteria: * 21 years of age or older * diagnosis of stage i to iiia breast cancer * within 1 to 5 years post primary cancer treatment (i.e., surgery, chemotherapy, and/or radiation therapy) * no diagnosis of recurrent breast cancer or a new primary cancer * able to provide meaningful consent exclusion criteria: * \< 21 years of age * unable to provide meaningful consent * surgically treated with bilateral mastectomy

Keywords: breast cancer surveillance mammography adherence